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ttp://dx.doi.org/10.1016/j.ajpath.2013.11.020Overexpression of osteopontin (OPN) is strongly associated with the invasiveness/metastasis of many
cancers, including melanomas. However, the molecular mechanisms of OPN in these processes remain
poorly understood. We found that forced expression of OPN in early vertical-growth-phase melanoma cells
dramatically increased their migration/invasion and growth/survival in a three-dimensional collagen I
gel. Neutralizing antibodies to OPN, integrin b1, and integrin avb3, but not to CD44, negated the effects
of OPN. Conversely, knocking down OPN in metastatic melanoma cells abrogated the invasive growth. OPN
overexpression activated and OPN knockdown inactivated avb3 and avb5 integrins, negligibly affecting
their expression. We further found OPN expression to inversely correlate with tetraspanin CD9 expression.
Early-stage melanoma cells displayed low OPN and high CD9 expression, and conversely, metastatic cells
displayed high OPN and low CD9 expression. Overexpression of OPN in vertical-growth-phase melanoma
cells induced down-regulation of CD9, and knockdown of OPN in metastatic melanoma cells up-regulated
CD9. Reversion of these CD9 changes abolished the effects of OPN. Furthermore, knockdown of CD9 in
early-stage melanoma cells stimulated their invasive capacity in three-dimensional collagen. Similarly,
microarray analyses of benign nevi and primary melanomas from different stages revealed an inverse
correlation between OPN and CD9. These data suggest that OPN promotes melanoma cell invasion by
activating integrin avb3 and down-regulating CD9, a putative metastasis suppressor. (Am J Pathol 2014,
184: 842e858; http://dx.doi.org/10.1016/j.ajpath.2013.11.020)Supported by the Academy of Finland (E.H.), Finnish Cancer Organiza-
tions (E.H.), Helsinki University Central Hospital Research Funds (De-
partments of Dermatology and HUSLAB) (O.S., S.V., and E.H.), and the
Helsinki Graduate Program in Biotechnology and Molecular Biology (J.S.).
Disclosures: None declared.Melanomas have a high tendency to locally invade and
subsequently disseminate/metastasize to distant sites,
resulting in high morbidity and mortality rates. In recent
years, we have learned much about the genetic changes
associated with melanoma development,1e5 but our knowl-
edge of the molecular mechanisms involved in melanoma
cell invasion and metastasis is less advanced. Further, it has
become increasingly evident that not only the tumor cells, but
also the tumor microenvironment, composed of various
extracellular matrix components and stromal cells, plays an
important role in tumor invasion and metastasis.6 Normally,
the extracellular matrix, for example the dermal collagen I
matrix, forms a barrier to limit the invasion and outgrowth of
melanoma cells,7,8 but in response to intrinsic and environ-
mental cues, the melanoma cells and tumor-associated stro-
mal cells can produce new extracellular matrix proteins and
other factors that favor invasion and metastasis.9e11 Becausestigative Pathology.
.these genes/proteins triggering metastasis may be common to
many cancers, they are attractive targets for the development
of new drugs aimed at preventing cancer deaths.
We and others have previously found that up-regulation of
a secreted phosphoprotein, secreted phosphoprotein 1/
osteopontin (SPP1/OPN), is strongly associated with mela-
noma invasion10,12 and sentinel lymph node metastasis.10
OPN is also reported to act as a molecular prognostic
marker for lymph node metastasis and the disease-free or
overall survival of melanoma patients.13,14 The up-regulation
of OPN expression has also been related to invasion and
Osteopontin and CD9 in Melanoma Invasionmetastasis, and poor prognosis in many other cancer types,
such as breast,15,16 lung,17,18 ovarian,19,20 liver,21 colon,22
and other cancers.23 Besides the tumor cells, several tumor-
associated stromal cells may also produce OPN and
contribute to tumor progression.24,25 OPN is a multifunc-
tional protein that can enhance proliferation, prevent
apoptosis, contribute to angiogenesis, and promote invasion
of various cancer cells.26e33 OPN can bind to several integrin
receptors, including avb1, avb3, avb5, avb6, a4b1, a5b1, a8b1,
and a9b1.
28,33,34 The arginine-glycine-aspartate (RGD) motif
of OPN is the major binding site for integrins, but the binding
site for a9b1 is SVVYGLR.
35 OPN is also able to bind CD44
receptors.36 Thus, the interaction of OPN with these cell-
surface receptors can activate various intracellular signal
transduction pathways and downstreammolecules regulating
cell behavior, such as AKT, NF-kB, and c-MET.33,37,38
However, little is still known about the downstream mole-
cules involved in the regulation of the OPN-promoted inva-
sion and metastasis.
In this study, we made use of previous studies on OPN in
various cancers and microarray analyses of early vertical-
growth-phase (VGP) melanoma cells and metastatic mela-
noma cells, and studied early-stage melanoma cells engineered
to overexpress OPN, and metastatic melanoma cells knocked
down in OPN expression, to further our understanding of the
actions of OPN and identify molecules regulating the OPN-
promoted invasion and growth of melanoma cells. We show
that OPN is particularly important for the melanoma cell
migration/invasion and growth in three-dimensional (3D)
collagen I matrix, and that activation of integrin avb3 and
down-regulation of tetraspanin CD9 are key events in the in-
vasion process. We further show that knocking down CD9 in
early VGPmelanoma cells provides themwith a high invasive
capacity. Finally, we show that the expression levels of OPN
and CD9 inversely correlate in clinical specimens of benign
nevi and invasive melanomas.
Materials and Methods
Cell Culture
The VGP WM115 and G-361 melanoma cells (ATCC; LGC
Promochem, Stockholm, Sweden) and the early VGP
WM793 melanoma cells and metastatic WM239 melanoma
cells (from a lymph node metastasis),39 kindly provided by
Dr. Meenhard Herlyn (Wistar Institute, Philadelphia, PA),
and their transfectants were grown in RPMI 1640 medium
containing antibiotics (penicillin, streptomycin) and 10%
fetal bovine serum (Invitrogen/Life Technologies, Carlsbad,
CA) at 37C in a 5% CO2 atmosphere.
Plasmids and Transfection
The human OPN cDNA-containing pcDNA3.1 vector [OP10/
pcDNA3, kindly provided by Dr. Ann Chambers (University
of Western Ontario, London, ON, Canada)],40,41 the humanThe American Journal of Pathology - ajp.amjpathol.orgCD9 cDNA-containing pZeoSV vector (pZeoSV-CD9),
kindly provided by Dr. Isao Tachibana (Osaka University,
Osaka, Japan),42 empty pcDNA3.1 and pZeoSV vectors
(Invitrogen/Life Technologies), empty pLKO.1 vector, and
the Expression TRC CD9 shRNA set (both from Open Bio-
systems/Thermo Fisher Scientiﬁc, Huntsville, AL) were
transfected into WM793, G-361, and WM239 cells using
Lipofectamine 2000 (Invitrogen/Life Technologies) according
to the manufacturer’s instructions. Two days after transfection,
the cells were subjected to selection with neomycin (for
pcDNA3.1 vectors) or puromycin (for pLKO.1-based vec-
tors), and pools of stable transfectants and individual clones
(isolated by cylinder cloning) were used for experiments.
Generation of Cell Lines with a Tetracycline-Inducible
System for Expression of Sense or Antisense OPN cDNA
The full-length human OPN cDNA was released from the
pcDNA3.1 vector and subcloned into a blunt-ended induc-
ible pLRT expression vector.43 The ligation products were
analyzed by automated sequencing (ABI PRISM 3100 Ge-
netic Analyzer; Applied Biosystems/Life Technologies,
Foster City, CA) to determine the fragment orientations. The
pLRT-OPN sense and antisense plasmids were transfected
into WM793 and WM239 cells, respectively, using Lip-
ofectamine 2000 reagent, and stable transfectants were
selected using blasticidin (5 mg/mL). Individual clones were
picked up by cylinder cloning and tested for their induc-
ibility of OPN expression (or antisense expression) by
adding doxycycline (Sigma-Aldrich, St Louis, MO).
Lentiviral shRNA Transduction
WM239 cells were grown to 60% conﬂuency and infected
with shRNA lentiviral particles targeting OPN (sc-37252-
SH, Santa Cruz Biotechnology, Dallas, TX), or with nega-
tive (scrambled) control shRNA particles (sc-108080) in the
presence of 10 mg/mL Polybrene (hexadimethrine bromide).
After 72 hours of transduction, the cells were collected for
further experiments. Transductions were performed twice in
duplicates in 24-well plates.
Cell Migration and Invasion Assays in 3D Matrices
The 3D collagen I gel invasion/migration assays were per-
formed as described previously.9,44,45 Brieﬂy, 1.5 to 2.0 104
cells in 100 mL of RPMI 1640were seeded onto collagen I gels
cast in 24-well plates (400mL of collagen I/well, 2 mg/mL; BD
Biosciences, Franklin Lakes, NJ) and allowed to adhere for 1
hour at 37C. Excess RPMI 1640 was removed, and a second
300-mL collagen I gel layer was cast above the cells. Finally,
500 mL of RPMI 1640 containing 10% fetal bovine serum was
added on top of the collagen I gel matrix. In the experiments
with function-blocking antibodies, the neutralizing antibodies
to OPN (R&D Systems, Minneapolis, MN), integrin b1 (6S6;
EMD Millipore, Billerica, MA), integrin avb3 (LM609;843
Yin et alMillipore) or CD44 (IM7; BD Biosciences), or isotype control
antibodies (10 mg/mL) were added into the collagen I gel and
the growth medium. The growth medium was replenished
every third day. The growth pattern and morphology of the
cells was documented daily by phase-contrast microscopy and
photography. The 3D Matrigel invasion assays were per-
formed as previously described.11,44e47 The assays were
repeated at least three times.
Boyden Chamber/Transwell Migration Assays
Migration of the cells was additionally analyzed using
collagen Iecoated Falcon cell-culture inserts (BD Bio-
sciences), as described previously.48
Adhesion/Spreading Assays
Cell-adhesion assays were performed on 96-well plates
coated with plasma ﬁbronectin, collagen I, collagen IV, and
vitronectin, and with bovine serum albumin as a negative
control.45
Cell Proliferation Analysis
Cells were seeded in triplicate in 6-well plates or in 3D
collagen I gel matrix in 24-well plates. At various time points,
the cells cultured in two-dimensions (2D) were detached with
trypsin, and the cells cultured in 3D collagen I gel were har-
vested by centrifugation at 300  g for 5 minutes, after
digestion of the gel with collagenase (0.2 mg/mL in PBS, for
90 minutes at 37C; Sigma-Aldrich). Cells were counted by
trypan blue exclusion.
Annexin V Apoptosis Assays
Cells were seeded on 24-well plates coated with 350 mL of
collagen I gel in serum-free medium. After 36 hours,
cellular apoptosis (phosphatidylserine externalization) was
detected by annexin V staining using the Annexin V-FITC
kit (BD Biosciences). Cell images were documented with a
ﬂuorescent microscope (Axiophot 2; Carl Zeiss, Oberko-
chen, Germany). The percentage of annexin Vepositive
cells was calculated from three randomly selected ﬁelds.
Preparation of Secreted Proteins
Secreted proteins from the cell-culture media were collected
and concentrated using Amicon Ultracel-10 centrifugal ﬁl-
ters (MWCO 10,000; Millipore), and equal amounts of
proteins (10 to 25 mg) were subjected to Western blot
analysis.45,46,49
Western Blot Analysis
Western blot analyses of whole-cell protein lysates and
secreted proteins were performed essentially as described
previously,47,49 except that the analysis of CD9 was844performed under nonreducing conditions. Proteins (10 to 20
mg) were run in SDS-PAGE (5% to 10%) and transferred
onto a nitrocellulose membrane. The ﬁlters were incubated
in blocking buffer overnight, and then incubated with mouse
monoclonal antibodies (mAb) against OPN (Enzo Life
Sciences, Farmingdale, NY), CD9 (MM2/57; EMD Milli-
pore), and b-actin (Sigma-Aldrich) for 4 to 6 hours. The
proteins were detected by enhanced chemiluminescence
(Pierce antibodies; Thermo Fisher Scientiﬁc, Rockford, IL).
Band densities were quantiﬁed using ImageJ version 1.44
(NIH, Bethesda, MD).
Fluorescence-Activated Cell Sorting Analysis
The cell-surface expression of tetraspanin CD9 and integrins
avb3 and avb5 were evaluated by ﬂuorescence-activated cell
sorting (FACS) analysis. Cells were detached with 1 mmol/L
EDTA in PBS and washed in blocking solution (PBS with
either 0.5% bovine serum albumin or normal goat serum). The
cells (1.0  105) were then incubated with 1.0 mg of mouse
mAb to CD9 (ALB6; Beckman Coulter, Brea, CA), mouse
mAb to integrin avb3 (LM609), or mouse mAb to avb5 (P1F6;
Santa Cruz Biotechnology) for 1 hour on ice, followed by
sequential incubation with biotinylated secondary antibody and
streptavidin-phycoerythrin, or Alexa Fluor 488econjugated
secondary antibody (Molecular Probes/Life Technologies).
Finally, the expression levels of CD9 and integrins avb3 and
avb5 were analyzed using a ﬂow cytometer (FACScan, FAC-
SAria II, or BD Accuri C6; BD Biosciences).
The amounts of active integrin avb3 were measured with a
monovalent ligand-mimetic WOW-1 antibody (Fab frag-
ment) (generously provided by Dr. Sanford J. Shattil, Uni-
versity of California, San Diego, CA),50 using Alexa Fluor
488econjugated goat anti-mouse IgG (HþL) F(ab)2 (Mo-
lecular Probes/Life Technologies) as the secondary antibody.
Immunoﬂuorescence Staining of Actin
Cells were cultured on top of thick collagen I matrix coated
onto glass coverslips, and ﬁxed with 3.5% paraformaldehyde.
F-actin was stained with Alexa Fluor 594econjugated phal-
loidin (Molecular Probes/Life Technologies). Fluorescence
was visualized by using a Zeiss Axioplan 2 microscope and
Axiophot2 photo module (Carl Zeiss), equipped with a
Hamamatsu CCD digital camera (Hamamatsu Photonics,
Hamamatsu City, Japan).
Immunohistochemical Analysis of Cells Grown in 3D
Collagen I Gels
For immunohistochemical analysis of the cells grown within
the thick 3D collagen I matrices, the gels were frozen in
liquid nitrogen or ﬁxed with formalin, embedded in parafﬁn,
and cut into 5-mm sections. The sections were then examined
by a routine immunohistochemical process as described.9
After deparafﬁnization, rehydration, heat-induced epitopeajp.amjpathol.org - The American Journal of Pathology
Osteopontin and CD9 in Melanoma Invasionretrieval, and endogenous peroxidase blockage, the slides
were incubated with rabbit anti-Ki67 mAb (SP6; Abcam,
Cambridge, UK).
RT-PCR Analysis
Total RNAs were extracted from cells with the RNeasy kit
(Qiagen, Crawley, UK). RNA quality/quantity was deter-
mined using the NanoDrop ND-1000 spectrophotometer
(Thermo Fisher Scientiﬁc, Waltham, MA). One microgram
of total RNA was reverse transcribed to cDNA. The primers
of the different candidate genes and PCR conditions are
listed in Table 1 and Kapyla et al.51 The PCR products were
run on 2% agarose gels. After electrophoresis, the gels were
stained with GelStar nucleic acid gel stain (Cambrex Bio
Science Rockland, Rockland, ME). The bands were visu-
alized and documented with Alpha Imager HP and Alpha
Easer Software version 5.01 (Alpha Innotech Corporation,
San Leandro, CA).
Patient Samples
Fresh biopsies from benign nevi (n Z 12) and primary
melanomas (n Z 20) from healthy volunteers and mela-
noma patients were obtained by surgical resection at Hel-
sinki University Central Hospital, Helsinki, Finland. The
study was approved by the Ethics Committee of the Helsinki
University Central Hospital, and informed consent was
obtained from the patients.Table 1 Primer Sequences and PCR Conditions
Gene name Polarity Sequence
Osteopontin Forward
Reverse
50-CCAAGTAAGTCCAACGAA
50-GGTGATGTCCTCGTCTGT
CD9 Forward
Reverse
50-ACTGTTCTTCGGCTTCCT
50-CACTGCGCCGATGATGTG
Integrin a1 Forward
Reverse
50-CACAGGGATCCGTCAGCC
50-GTGGCTGTCGACAGCTGT
Integrin a2 Forward
Reverse
50-CACAGGGATCCCCTGATT
50-GTGGCTGAATTCAACAGT
Integrin a10 Forward
Reverse
50-CAGGGATCCCCAACATAC
50-GGCTGAATTCCCCTTCAA
Integrin a11 Forward
Reverse
50-CAGACCTACATGGACATC
50-CATCTCCAGCCCAAAGGA
Integrin av Forward
Reverse
50-TGGAGCATCTGTGAGGTC
50-AACCATTCCCAAAGTCCT
Integrin b1 Forward
Reverse
50-TGCGAGTGTGGTGTCTGT
50-TGACCACAGTTGTTACGG
Integrin b3 Forward
Reverse
50-GATGCATCCCACTTGCTG
50-CATTGTTGAGGCAGGTGG
Integrin b5 Forward
Reverse
50-ACCAGGAGGCTGTGCTAT
50-TGTGCGTGGAGATAGGCT
b-actin Forward
Reverse
50-GCTCGTCGTCGACAACGG
50-CAAACATGATCTGGGTCA
GAPDH Forward
Reverse
50-GGTGAAGGTCGGAGTCAA
50-CAAATGAGCCCCAGCCTT
The American Journal of Pathology - ajp.amjpathol.orgMicroarray Analysis
Microarray analyses with the Affymetrix Human Genome
U133 Plus 2.0 arrays were performed according to the
manufacturer’s protocols (Affymetrix, Santa Clara, CA), as
previously described.10,48 Brieﬂy, total RNAs were extrac-
ted using the RNeasy kit, and reverse-transcribed to cDNAs.
After in vitro transcription, the biotinylated cRNAs were
fragmented and hybridized to the chips. Washing and
staining (with antibody ampliﬁcation) was performed on an
Affymetrix Fluidics 450 station, and the signals were
scanned. The data were then processed by RMAExpress
version 1.0.5, released May 22, 2010 (http://rmaexpress.
bmbolstad.com).
Statistical Analysis
Data analyses were performed using a two-tailed Welch’s
t-test. P < 0.05 was considered statistically signiﬁcant.
Results
Ectopic Overexpression of OPN in WM793 Melanoma
Cells Confers the Cells with the Ability to Migrate/
Invade in 3D Collagen I
To examine the functional roles of OPN in melanoma cells,
an early VGP melanoma cell line WM793 with low OPN
expression was transfected with a constitutive expression
vector for OPN or an empty control plasmid. After selectionAnnealing (C) Cycles
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Figure 1 Ectopic expression of OPN confers the
early VGP WM793 melanoma cells with the ability to
migrate/invade in 3D collagen I matrix. A: RT-PCR
analysis of osteopontin RNA expression in WM793
cells transfected with an empty control vector
(CTRLp; pool of transfectants) and osteopontin
expression vector (OPNp, OPN5, and OPN8; pool of
transfectants and two clones). B: Western blot
analysis of osteopontin protein levels in the condi-
tioned media and cellular lysates of the control and
osteopontin-transfected cells. C: Culture of the
control cells and osteopontin transfectants in the
middle of a 3D collagen I gel for 36 hours. D: The
percentage of cells with a spread/elongated
morphology after the culture in collagen I. E: Actin
(Alexa Fluor 594econjugated phalloidin) staining of
the control and osteopontin-transfected cells grown
on thick collagen I matrix for 36 hours. Data are
expressed as means  SD of three replicates (each
analyzed in three randomly chosen ﬁelds) (D).
P < 0.001, CTRLp versus OPNp; P Z 0.002, CTRLp
versus OPN5; and P < 0.001, CTRLp versus OPN8 (D).
Original magniﬁcationZ 100 (C and E).
Yin et alof stable transfectants, the initial pools of transfectants
harboring the control or OPN expression plasmids, and two
clonal isolates of the latter (OPN5 and OPN8) with different
levels of OPN protein expression (Figure 1, A and B), were
subjected to more detailed analyses. As shown by Western
blot analyses of the concentrated conditioned media and cell
lysates (Figure 1B), the amount of secreted OPN was
markedly increased in the OPN transfectants, whereas the
corresponding intracellular levels of OPN were only slightly
increased, if at all. These ﬁndings support the notion that
OPN mainly conducts its functions as an extracellular, so-
called matricellular protein.52846The OPN-overexpressing WM793 cells did not show any
noticeable morphological change, and retained an epithe-
lioid morphology, when grown on 2D tissue culture dishes
in the presence of serum (Supplemental Figure S1A).
However, the OPN transfectants showed an enhanced
growth rate as compared with the control cells
(Supplemental Figure S1B).
We then analyzed the behavior of the cells when
embedded in 3D collagen I gels, to mimic the cellular
growth and migration/invasion conditions of melanoma
cells in the collagen-rich dermis. After 24 hours of culture,
the control cells appeared to be in poor condition, displayingajp.amjpathol.org - The American Journal of Pathology
Figure 2 The migratory/invasive activity of the
OPN-transfected WM793 cells is inhibited by
neutralizing antibodies to OPN and integrin avb3,
in the absence of any increases in the mRNA
expression of the integrin avb3 and avb5 receptor
subunits. A: The migratory/invasive capability of
the OPN-transfected WM793 cells (OPNp) in 3D
collagen I in the presence of 10 mg/mL isotype
control antibodies (IgG) and neutralizing anti-
bodies to osteopontin (OPN Ab). B: The percentage
of cells with a spread/elongated morphology after
incubation of the cells with the control and OPN
antibodies (A). C: The migratory/invasive capa-
bility of the OPN-transfected WM793 cells in 3D
collagen I in the presence of 10 mg/mL isotype
control antibodies (IgG) and neutralizing anti-
bodies to integrin avb3 (avb3 Ab) for 36 hours. D:
The percentage of cells with a spread/elongated
morphology after incubation of the cells with the
control and integrin avb3 antibodies. E: RT-PCR
analysis of the integrin subunits ITGAV, ITGB3,
and ITGB5. Actin (ACTB) was used as a control.
Data are expressed as means  SD of three repli-
cates (B and D). P Z 0.244, Ctrl versus IgG;
PZ 0.001, Ctrl versus OPN Ab (B); P < 0.001, Ctrl
versus integrin avb3 antibodies (D). Original
magniﬁcation, 100 (A and C). Ctrl, control.
Osteopontin and CD9 in Melanoma Invasiona round/roundish or oval morphology. By contrast, the
OPN-overexpressing cells showed an elongated, spindle-
shaped, or dendritic morphology typical of a migratory/
invasive phenotype, and the cells contacted each other,
forming a lattice (Figure 1, C and D). We further stained
actin in the cells grown on top of thick 3D collagen I gels,
and found the OPN-overexpressing cells to form
invadopodia-like projections that extended into the 3D
collagen I matrix (Figure 1E). In addition, the OPN-
overexpressing WM793 cells were found to show
increased migratory activity in Boyden chamber/Transwell
assays, using collagen Iecoated membranes (Supplemental
Figure S2, A and B).The American Journal of Pathology - ajp.amjpathol.orgTo conﬁrm that the invasive phenotype of the OPN
transfectants in 3D collagen I gels was speciﬁcally associ-
ated with the production of OPN, and not due to any inci-
dental transfection-related genetic alterations, a neutralizing
antibody against human OPN was added to the assay sys-
tem. Notably, the acquisition of the invasive phenotype by
the OPN-overexpressing cells was effectively blocked in the
presence of the OPN-neutralizing antibodies (Figure 2, A
and B, and Supplemental Figure S3, AeD).
Because OPN is known to act as an attachment factor,28 we
studied whether the differential behavior of the control and
OPN-overexpressing cells could be due to the secreted OPN
promoting cell adhesion. However, although exogenous OPN847
Figure 3 The overexpression of OPN does not increase the total levels
of avb3 integrin on the cell surface, but increases the amounts of active
avb3 integrin. FACS analysis of the expression of integrin avb3 (detected
with LM609 antibody) (A), active integrin avb3 (detected with WOW-1
antibody) (B), and integrin avb5 (detected with P1F6 antibody) (C) on
the cell surface of the transfectants. For experimental details, see
Materials and Methods. Black lines indicate unlabeled cells; green lines,
isotype controls; blue lines, empty vector-transfected WM793 cells
(CTRLp) probed with speciﬁc antibodies; and red lines, OPN-transfected
WM793 cells (OPNp) probed with speciﬁc antibodies. The M1 marker de-
notes the proportion of the cells considered to be positively stained for
the integrins.
Yin et al
848was found to clearly support the attachment of the parental
WM793 cells (Supplemental Figure S4A), the OPN-over-
expressionepromoted increase in invasion in 3D collagen I
gels could not be explained by OPN acting as an attachment
factor, at least to any larger extent, for the following reasons.
First, the parental WM793 cells with low OPN expression
can attach very well to collagen I alone (Supplemental
Figure S4B). Second, the OPN-overexpressing cells did
not spread within the 3D collagen I gels when incubated in
the presence of neutralizing antibodies to integrin b1
(Supplemental Figure S5, A and B), which block the cellular
attachment to collagen I through the collagen receptors
a1b1, a2b1, a10b1, and a11b1. In this context, it is also
noteworthy that the overexpression of OPN did not
increase the expression of collagen receptors (Supplemental
Figure S5C), which could have contributed to the different
behavior of the parental WM793 cells and the OPN over-
expressers in the collagen I gels.
We then studied the possible role played by integrin avb3,
a major receptor for OPN, because it is known to be up-
regulated in VGP and metastatic melanomas,53 it can
rescue melanoma cells from apoptosis in 3D collagen,7 and
its forced expression can convert radial-growth melanoma
cells to VGP.54 We found that the addition of function-
blocking/neutralizing antibodies to avb3 (LM609) to the
3D collagen I cultures of the OPN-overexpressing WM793
cells resulted in about 60% inhibition of cell spreading or
survival (Figure 2, C and D, and Supplemental Figure S6,
AeD). In this context, it is notable that the over-
expression of OPN did not cause any increase in the mRNA
expression levels of avb3 integrin subunits, or those of
integrin avb5, another receptor for OPN. Rather, the integrin
b3 mRNA levels appeared to be slightly decreased
(Figure 2E). Likewise, analysis of the cell-surface protein
expression of integrin avb3 by ﬂow cytometry with the
LM609 antibody (which recognizes both the active and
inactive conformations of avb3) suggested a small decrease
in avb3 in the OPN-overexpressing cells as compared with
the control cells, although all of the cells were positive for
integrin avb3 expression (Figure 3A). We then assessed the
amounts of active avb3 integrin on the cells with the
monovalent ligand-mimetic antibody WOW-1, which
selectively binds to conformationally active avb3.
50 In these
experiments, the OPN-overexpressing WM793 cells were
found to display markedly (4.9-fold) higher amounts of
active avb3 than the control cells (Figure 3B), indicating that
OPN activates avb3 integrin. OPN overexpression was also
found to slightly increase the cell-surface expression of
integrin avb5, as determined with the P1F6 antibody
(Figure 3C).
Because OPN is also known to bind the CD44 surface
receptors and thereby promote the migration/invasion of
many cancer cells,27,33,55,56 we tested whether the same
could also be true for the OPN-overexpressing WM793
melanoma cells. However, administration of the CD44
functioneblocking antibodies did not interfere with theajp.amjpathol.org - The American Journal of Pathology
Figure 4 The overexpression of OPN is associ-
ated with an increased growth rate of the cells in 3D
collagen I. A: Growth of the control (CTRLp) and
osteopontin-transfected (OPNp) cells in 3D collagen I
for 1 and 6 days. B: Growth curves of the control
(CTRLp) and osteopontin-transfected cells (OPNp,
OPN5, and OPN8) grown in 3D collagen I gel for 14
days. The cell numbers were counted after digestion
of the collagen gel with collagenase. C: Immuno-
histochemical analysis of the Ki67 proliferation
marker in the control and OPN-transfected WM793
cells grown in the collagen I gel for 14 days. D: The
percentage of Ki67-positive cells (red/brown nuclei)
after the culture of the cells within collagen I for 2
weeks. Data are expressed as means  SD of three
parallel cultures (B). PZ 0.001, CTRLp versus OPNp;
P Z 0.007, CTRLp versus OPN5; P Z 0.003, CTRLp
versus OPN8 at 14 days of culture (B). P Z 0.030,
CTRLp versus OPNp; P Z 0.009, CTRLp versus OPN5;
P Z 0.038, CTRLp versus OPN8 (D). Original magni-
ﬁcation, 100 (A); 200 (C).
Osteopontin and CD9 in Melanoma Invasioninvasion/migration of these cells in 3D collagen I gels
(Supplemental Figure S7, AeF).OPN Overexpression Promotes the Survival and
Proliferation of WM793 Cells in 3D Collagen I Matrix
Because OPN is known to contribute to antiapoptotic
signaling of melanocytes in collagen gels,57 we analyzed the
survival of the control and OPN-overexpressing WM793
cells when grown on thick collagen I gels. As shown in
Supplemental Figure S8, A and B, the overexpression of
OPN protected the WM793 cells from apoptosis, as
assessed by annexin V staining.
Next, we analyzed the growth/proliferation of the cells
within the 3D collagen I matrix by microscopy and cell
counting (after digestion of thematrixwith collagenase). All of
the OPN transfectants showed a continuously increased
growth rate/proliferation during the follow-up period for 1 to 2
weeks, whereas the control cells could not proliferate (except
very marginally in the beginning) and appeared to die during
prolonged culture (Figure 4, A and B, and data not shown).We
further analyzed the cells grown inside the collagen gel for 2
weeks for the expression of the proliferation marker Ki-67 by
immunohistochemistry in situ, after paraformaldehyde ﬁxa-
tion, parafﬁn embedding, and vertical sectioning of the gels.
As expected, only relatively few living control cells were
detected in the sections at this stage anymore, whereas the
OPN transfectants were detected in abundance. Notably, theThe American Journal of Pathology - ajp.amjpathol.orgexpression of Ki-67 was up-regulated in the OPN trans-
fectants, and the number of the Ki-67epositive cells as well as
the intensity of the staining appeared to correlate with the OPN
expression level (Figure 4, C and D).
We further analyzed the invasive growth ability of the OPN-
overexpressing cells embedded in thick 3D Matrigel (a
reconstituted basement membrane matrix), where the invasion
requires proteolytic activity. As shown in Supplemental
Figure S9, OPN overexpression was also found to promote
the invasive growth ofWM793 cells in 3DMatrigel, but in this
matrix, the control cells also showed some invasive growth
potential, consistent with our recent study.11 Thus, OPN ap-
pears to be more critical for the migration/invasion and growth
of WM793 cells in 3D collagen I matrix than in Matrigel.
Overexpression of OPN Down-Regulates CD9 Expression
To identify molecules involved in the OPN-promoted
invasive growth of melanoma cells in 3D collagen I gels,
we ﬁrst examined our genome-wide microarray data on
early VGP WM793 melanoma cells that have a low OPN
expression level, and metastatic WM239 melanoma cells
that have high OPN expression,45 as well as public micro-
array databases on other early-stage primary and metastatic
melanoma cell lines. Interestingly, the expression of CD9, a
member of the tetraspanin family of transmembrane pro-
teins,58 was found to often correlate inversely with OPN in
the early-stage primary (eg, WM3211, SbC12, WM1361A,
WM1552C, and WM793) and metastatic (eg, D24, D28,849
Figure 6 Ectopic re-expression of CD9 in the OPN-overexpressing
WM793 cells abrogates the migratory/invasive activity of the cells in 3D
collagen I. A: Western blot analysis of CD9 expression in OPN-
overexpressing WM793 cells (OPN5) transfected with an empty control
vector and CD9 expression vector. B: The migratory/invasive capability of
the OPN-overexpressing WM793 cells (OPN5) transfected with an empty
vector and CD9 expression vector in 3D collagen I. C: The percentage of
cells with a spread/elongated morphology. Similar results were also ob-
tained in the other OPN transfectants (OPNp and OPN8). Data are expressed
as means  SD of three replicates (C). P < 0.001 (C). Original magniﬁ-
cation, 100 (B).
Figure 5 The expression of OPN is increased and that of CD9 decreased
during the development and progression of melanomas. A: RT-PCR analysis
of the OPN and CD9 RNA expression levels in VGP melanoma cell lines
WM793 and WM115, metastatic melanoma cell line WM239, and primary
melanocytes. B and C: Analysis of the protein expression levels of CD9 in
the control and OPN-transfected WM793 cells by Western blotting and FACS,
respectively. Actin (ACTB) was used as a loading control. Relative protein
expression levels of CD9 in the control and OPN-transfected WM793 cells are
shown below the Western blot lanes (B) and the M1 bars (C). In C, gray
lines and dark areas represent isotype controls and cells stained with CD9
antibody, respectively. The M1 marker denotes CD9 positive cells.
Yin et alD35, LOXIMV1, WM266-4, and WM239) melanoma cell
lines (Supplemental Table S1).45,59,60 Our RT-PCR analyses
conﬁrmed that the VGP WM793 and WM115 cells with low
OPN expression had high CD9 expression, and conversely,
the metastatic WM239 cells with high OPN expression
(derived from the same patient as the primary WM115 cells)
displayed low CD9 expression (Figure 5A). In further850support of the idea of the expressions of OPN and CD9
correlating negatively, our microarray and RT-PCR ana-
lyses revealed very low expression of the OPN mRNA and
high expression of the CD9 mRNA also in primary mela-
nocytes (Figure 5A and data not shown).
To further conﬁrm that OPN expression is associated with
down-regulation of CD9, we performed RT-PCR andWestern
blot analyses of CD9 in the OPN-transfected WM793 cells.
Both the CD9 mRNA (Supplemental Figure S10A) and CD9
protein levels (Figure 5B) were signiﬁcantly decreased in the
OPN transfectants as compared to the control cells. Similar
results were obtained with another VGP melanoma cell line,
G-361 (Supplemental Figure S10B).
In addition, we evaluated the cell-surface expression of
CD9, and these analyses conﬁrmed the reduced expression
of CD9 on the plasma membrane of the OPN transfectants
as well (Figure 5C). To obtain still more convincing evi-
dence for the regulation of CD9 by OPN, we transfected theajp.amjpathol.org - The American Journal of Pathology
Figure 7 Down-regulation of OPN in metasta-
tic WM239 melanoma cells inhibits the invasive
growth of the cells in 3D collagen I and the
attachment of the cells to vitronectin. A: RT-PCR
analysis of the OPN and CD9 RNA expression
levels in WM239 cells transduced with lentiviral
control shRNAs or shRNAs targeting OPN. B:
Growth curves of the control shRNA- and OPN
shRNA-expressing WM239 cells in 2D culture in
plastic Petri dishes. C: Culture of the control
shRNA- and OPN shRNA-expressing WM239 cells in
3D collagen I gel for 24 hours. D: The percentage
of spread/elongated cells after culture of the
control and OPN-knockdown cells in collagen I gel
for 24 hours. E: Growth curves of the WM239 cells
transduced with control shRNA or OPN shRNA in 3D
collagen I gel. F: Attachment/spreading of the
OPN-knockdown cells on plasma ﬁbronectin (pFN),
collagen I (COL-I), collagen IV (COL-IV), and
vitronectin (VTN), with bovine serum albumin
(BSA) as a negative control. G: RT-PCR analysis of
the expression levels of integrins ITGAV, ITGB3,
and ITGB5 in the control shRNA- and OPN shRNA-
expressing WM239 cells. Actin (ACTB) was used
as a control. Data are expressed as means  SD of
at least three replicates (B and DeF). P Z 0.01,
WM239 ctrl shRNA versus WM239 OPN shRNA at 6
days of culture (B); P Z 0.005 (D); P Z 0.007,
WM239 ctrl shRNA versus WM239 OPN shRNA at 14
days of culture in 3D collagen I (E); P < 0.001
(VTN) (F). Original magniﬁcation, 100 (C). ctrl,
control.
Figure 8 The expression levels of integrins avb3 and avb5 on the cell
surface are not changed after the down-regulation of OPN in metastatic WM239
melanoma cells. FACS analysis of the expression of integrins avb3 (A) and avb5
(B) on the cell surface of the control shRNA- and OPN shRNA-expressingWM239
cells. Green lines indicate isotype controls; blue lines, control shRNA-
expressing WM239 cells probed with speciﬁc antibodies; and red lines, OPN
shRNA-expressing WM239 cells probed with speciﬁc antibodies. The M1 marker
denotes cells positively stained for the integrins.
Osteopontin and CD9 in Melanoma InvasionWM793 cells with a tetracycline-inducible OPN expression
vector system, enabling analysis of the effects of OPN in
exactly the same genetic context. As shown in Supplemental
Figure S11, the addition of increasing amounts of doxycy-
cline resulted in a progressive increase in the expression of
OPN, accompanied by a reciprocal, graded decrease in the
expression of CD9.
To assess the physiological signiﬁcance of the down-
regulation of CD9 by OPN overexpression, we restored
CD9 expression in the OPN-overexpressing WM793 cells
by transfection with a CD9 expression vector. Restoration of
the CD9 expression abolished the migratory/invasive ac-
tivity of the OPN-overexpressing cells (Figure 6, AeC),
indicating that the down-regulation of CD9 is essential for
the OPN-promoted cell migration/invasion in 3D collagen I.
Down-Regulation of OPN in Metastatic WM239
Melanoma Cells Increases CD9 Expression and Impairs
Invasive Growth
Next, we studied the effects of knocking down the high
expression of OPN in the metastatic WM239 cells by using a
lentiviral shRNA delivery system. Analysis of the pools of theThe American Journal of Pathology - ajp.amjpathol.orgcontrol and OPN shRNA transfectants already without
isolating clones revealed an efﬁcient down-regulation of OPN,
which was accompanied by an up-regulation of CD9 expres-
sion (Figure 7A and Supplemental Figure S12). In 2D culture851
Figure 9 Down-regulation of CD9 in VGP
WM793 cells induces an invasive phenotype and
enables the cell growth in 3D collagen I. A and
B: Analysis of the protein expression levels of
CD9 by Western blotting and FACS, respectively,
in WM793 cells and WM793 cells expressing the
control shRNA (pLKO) or shRNAs (sh1 to sh5)
targeting CD9. Relative protein expression
levels of OPN in the control shRNA- and CD9
shRNAs-transfected WM793 cells are shown
below the Western blot lanes (A) and the M1
bars (B). In B, gray lines and dark areas
represent isotype controls and cells stained
with CD9 antibody, respectively. The M1 marker
denotes CD9 positive cells. C: Culture of the
WM793 cells expressing the control or CD9
shRNAs in 3D collagen I gel for 36 hours. D: The
percentage of cells with spread/elongated
morphology after culture of the control or CD9
shRNA-expressing cells in collagen I for 36
hours. E: Growth curves of the control and CD9
shRNA-expressing WM793 cells in 3D collagen
I gels. Data are expressed as means  SD of
three replicates (D and E). P < 0.001, WM793-
pLKO versus WM793-CD9sh1; P < 0.001,
WM793-pLKO versus WM793-CD9sh2 (D).
P Z 0.006, WM793-pLKO versus WM793-
CD9sh1; P Z 0.006, WM793-pLKO versus
WM793-CD9sh2 at 14 days of culture (E). Orig-
inal magniﬁcation, 100 (C).
Yin et alconditions, the knockdown of OPN (and subsequent increase
in CD9) had no effect on the cell morphology but inhibited the
cell growth (Figure 7B), ﬁtting with the preceding ﬁndings on
the OPN-overexpressing WM793 cells (Supplemental
Figure S1). In 3D collagen I gels, in turn, the knockdown of
OPN affected both themorphology (spreading) and the growth
of the cells (Figure 7, CeE). The control shRNAetransfected
cells showed similar growth patterns to the parental WM239
cells (Supplemental Figure S13, AeC). The knockdown of
OPN by shRNA expression was further found to induce
apoptosis in the WM239 cells (Supplemental Figure S13, D852and E), similar to that reported for hepatocellular carcinoma
cells.31 During prolonged culture of the shRNA transfectant
pool, a selection against the high OPN shRNA expressers with
gradual diminution of the growth inhibitory effect was
observed, as expected (Figure 7E and data not shown). Similar
results were also obtained with the WM239 cells transfected
with a tetracycline-inducible antisense OPN expression system
(Supplemental Figure S14, AeC). Further studies of the
WM239 OPN-knockdown cells strengthened our prior con-
clusions on WM793 cells that OPN is not needed for the
attachment of melanoma cells to collagen I (or to collagen IVajp.amjpathol.org - The American Journal of Pathology
Figure 10 The development and progression of primary melanomas
is associated with up-regulation of OPN and down-regulation of CD9
expression. Analysis of the OPN and CD9 expression levels in human
benign nevi (n Z 12), thin primary melanomas (n Z 9, Breslow <2
mm; median thickness 1.2 mm; range, 0.6 to 1.7 mm), and thick primary
melanomas (n Z 11, Breslow 2 mm; median thickness 7.0 mm; range,
2.5 to 27 mm) by Affymetrix HG U133 plus 2.0 arrays. Error bars indi-
cate SD.
Osteopontin and CD9 in Melanoma Invasionor plasma ﬁbronectin), but showed that it is involved in the cell
adhesion to vitronectin (Figure 7F). Here, it should again be
noted that the attachment and spreading of the OPN-
knockdown cells on vitronectin was profoundly inhibited
without any decreases in the mRNA or protein expression
levels of the integrins avb3 or avb5, the main cellular receptors
for vitronectin (Figure 7G and Figure 8, A and B). We further
studied the signiﬁcance of CD9 up-regulation for the OPN
knockdowneinduced effects on the behavior of WM239 cells
in 3D collagen I culture by knocking down CD9. The
knockdown of CD9 expression by CD9 shRNA1 transduction
was found to largely abolish the inhibitory effects of OPN
shRNA expression (Supplemental Figure S15, A and B, and
Figure 7, C and D, for comparison).
Knockdown of CD9 Stimulates the Invasive Growth of
WM793 Melanoma Cells
Next, we studied the importance of CD9 in the regulation of
the invasive growth ofmelanoma cells in 3D collagen I matrix,
and asked whether the down-regulation of CD9 expression by
itself could induce an invasive phenotype. For this, the early
VGP WM793 cells were transfected with plasmids encoding
ﬁve different shRNAs to CD9 or with control plasmids
(pLKO.1 or the nontarget shRNA control vector). Western
blot (Figure 9A) and FACS (Figure 9B) analyses conﬁrmed a
clear down-regulation of CD9 in four of the ﬁve shRNA
transfectants, two of which were selected for more detailed
studies. In this context, it should also be noted that the down-
regulation of CD9 was not associated with any reciprocal
changes in OPN expression (Supplemental Figure S16).
The invasion/migration assays of the cells in 3D collagen
I matrix demonstrated that knocking down the expression of
CD9 in WM793 cells resulted in a similar morphological
change as that observed with the WM793 cells over-
expressing OPN. The cells became spindle-shaped and
larger in size, acquiring a mesenchymal cellelike appear-
ance characteristic of an invasive phenotype (Figure 9, C
and D). Similarly to the WM793 cells overexpressing OPN,
the CD9-knockdown cells showed a continuously increased
growth rate, whereas the control cells again, after 1 week of
marginal growth, started to die in the 3D collagen I matrix
(Figure 9E).
The Development of Invasive Primary Melanomas Is
Associated with Up-Regulation of OPN and
Concomitant Down-Regulation of CD9
To assess the possible physiological signiﬁcance of the
observed gene expression alterations, we examined our
microarray analyses of benign nevi and primary mela-
nomas (Soikkeli et al10 and unpublished data) for the
expression of OPN and CD9. First, we compared OPN and
CD9 expression in normal nevi (n Z 12) and a group of
patients (n Z 9) with thin melanomas (Breslow’s
depth <2 mm). The expression levels of OPN were veryThe American Journal of Pathology - ajp.amjpathol.orglow in normal nevi but showed a moderate, statistically
signiﬁcant (P Z 0.020) increase in thin melanomas,
whereas the expression levels of CD9 were high in normal
nevi and showed a minor, nonsigniﬁcant (P Z 0.61)
decrease in the thin melanomas (Figure 10). Analysis of a
larger number of patients will be needed to deﬁne the
precise association of the decrease in CD9 expression with
the development of early-stage invasive melanomas.
However, both the OPN and CD9 expression levels
showed highly signiﬁcant changes in the thicker mela-
nomas with increased invasiveness11 (n Z 11, Breslow’s
depth >2 mm) as compared to normal nevi (P Z 0.0014
and P Z 0.00019, respectively). The expression of OPN
mRNA was increased about 1000-fold, and the expression
of CD9 was decreased roughly twofold in the thick mel-
anomas (Figure 10). Similar results were obtained when
comparing our microarray data on normal nevi to those of
thin (n Z 4) and thick (n Z 10) melanomas deposited in
data banks (Supplemental Figure S17).
Discussion
The secreted phosphoprotein SPP1/OPN has been implicated
in the regulation of invasion and metastasis in a variety of
cancers, including melanoma. Notably, SPP1/OPN is one of
the most highly up-regulated genes/proteins in primary VGP
melanomas compared to in benign nevi,10,12,61 and in micro-
metastatic melanomas,10 and its analysis may be of clinical
value in prognostication13 and as a serological marker for
metastasis, particularly in conjunction with other
markers.62e64 In the metastatic cascade, OPN has particularly
been associated with sentinel lymph node metastasis.10,13,65853
Yin et alHowever, the mechanisms of OPN action in these steps of
melanoma progression remain largely elusive.
Here, we found that the ectopic overexpression of full-length
OPN cDNA inWM793 melanoma cells resulted in a markedly
increased secretion ofOPN,whereas the intracellular content of
OPN was only marginally increased. Thus, although the
secreted and intracellular forms of OPN have been documented
to have distinct cellular functions,66 our data suggest that
secreted OPN plays the major role in promoting melanoma
growth. This is further supported by our ﬁnding that OPN
neutralizing antibodies could block the growth of the OPN-
overexpressing WM793 cells. In this context, it may be note-
worthy that a speciﬁc splice variant of OPN (OPN-c lacking
exon 4) has been associated with the invasiveness of breast
cancer cells.67,68 However, we did not ﬁnd this isoform to be
expressed in the WM239 melanoma cells to any appreciable
extent (data not shown). The same has also been reported
recently in other human cancers.69 Thus, the expression of the
different isoforms of OPN appears to be cell-type speciﬁc.
We found that the overexpression of OPN confers the
WM793 melanoma cells with the ability to survive, migrate/
invade, and grow in 3D collagen I gel. Thus, OPN is also likely
to be important for the advancement of melanomas in the
dermal environment, where collagen I is the most abundant
extracellular matrix component. We further found that the
OPN-promoted migration/invasion and growth of melanoma
cells in 3D collagen was dependent on the activity of integrins
b1 andavb3. Differing somewhat from a previous publication,
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we did not ﬁnd integrin avb3 to be able to substitute for
integrin b1 in mediating cell attachment to collagen I during
culture in 3D collagen. Thismay be due to the fact that we used
acid-extracted collagen I (resulting in normal collagen cross-
linking), whereas Montgomery et al7 used protease-treated
collagen I for preparing the gel or, as suggested by the latter
authors, the collagen I was denatured by the action of cellular
proteases, enabling cell binding to the matrix through avb3. It
is also apparent from our data that the OPN-promoted survival/
growth of the OPN-transfected WM793 cells in collagen I
cannot be explained by the secreted (and deposited) OPN
substituting for integrin b1 in the cell attachment to collagen I.
Hence, these data, together with our studies of WM239 cells
knocked down in OPN expression by shRNAs, suggest that
OPN mainly promotes the migration/invasion and growth/
survival of melanoma cells in 3D collagen by acting as an
autocrine cytokine-like growth factor that activates the integrin
avb3 receptor (and/or the other integrin receptors binding
OPN). However, OPN may be involved in the regulation of
adhesion of melanoma cells to substrata other than collagen I.
Indeed, we found OPN to be essential for the adhesion of
WM239 melanoma cells to vitronectin.
Because the main receptors for vitronectin are the integrins
avb1, avb3, and avb5, and we found neither the overexpression
nor the down-regulation of OPN to cause any major changes in
the mRNA levels of the integrin subunits av, b1, b3, or b5 or in
the cell-surface expression of the avb3 and avb5 integrins, it is
highly likely that OPN regulates the activation state/854conformation of the av (b1, b3, and b5) integrins. Indeed, we
found OPN expression to increase the levels of active avb3
(measured with the WOW-1 antibody), whereas the total avb3
levels (measured with the LM609 antibody) on the cell surface
appeared to be slightly decreased (which is in line with the
observed slight decrease in integrin b3 mRNA expression).
However, we cannot totally exclude the possibility that in the
case of the LM609 antibody, the decreased ﬂuorescence in-
tensity observed in the OPN-overexpressing cells could also be
due to a decreased accessibility of the antibody to the target, eg,
as a result of OPN inducing avb3 integrin clustering or com-
plexing with other proteins (OPN itself as one possibility). The
WOW-1 antibody in turn as a monovalent Fab fragment is less
sensitive to these kinds of changes, and is thus expected to
reliably report the amounts of active avb3 on the cells.
Because vitronectin is abundantly present in serum and
deposited on the vessel walls, elastic ﬁbers in dermis, and
reticular ﬁbers in the lymph node cortex,70e72 it remains of
interest to study whether the OPN-mediated activation of av
(b1, b3, and b5) receptors and consequent binding of the
melanoma cells to vitronectin could also play a role in
melanoma cell migration/invasion in dermis and homing of
the metastatic cells in the lymph nodes. Indeed, it has been
shown previously by using frozen sections of human lymph
nodes that avb3 may be involved in the adherence and
metastasis of melanoma cells to the lymph nodes.73
Moreover, the secreted OPN by melanoma cells may also
activate stromal cells expressing avb3, such as endothelial
cells and macrophages, and thereby promote tumor angio-
genesis and other metastatic processes. All these data
together make integrin avb3 an attractive target for therapy.
Notably, several av-integrin antagonists are already in
clinical trials in melanoma.74,75
OPN is also known to signal through CD44 variant re-
ceptors in various cancers,27,33,56 but we did not ﬁnd the
blocking of CD44 with neutralizing antibodies to affect the
behavior of the WM793 OPN-overexpressing cells in 3D
collagen I. However, these data by no means exclude the
possibility that OPN could signal through CD44 in other
melanoma cells lines.76 It is notable, however, that our gene
expression analyses of several primary human melanocyte
and melanoma cell cultures or melanoma cell lines have not
revealed any major difference in CD44 expression, whereas
the expression of integrin avb3, especially that of the b3
subunit, appears to be markedly increased in the melanoma
cells (unpublished data). All together, these data support the
idea that, in human melanoma cells, OPN is mainly
signaling through the integrin receptors.
Interestingly, our microarray analyses of melanocytes, early
VGP melanoma cells, and metastatic melanoma cells revealed
OPN expression to correlate inversely with the expression of
tetraspanin CD9. In addition, the forced overexpression of
OPN in WM793 cells caused down-regulation of CD9, and
conversely, the knockdown of OPN in WM239 cells resulted
in up-regulation of CD9; and reversion of these changes in
CD9 by expression of CD9 cDNA and CD9 shRNAs,ajp.amjpathol.org - The American Journal of Pathology
Osteopontin and CD9 in Melanoma Invasionrespectively, negated the effects of OPN on cell migration/
invasion in 3D collagen I. Further, knocking down CD9 in
WM793 cells was found to induce an invasive phenotype,
similar to that caused by OPN overexpression. In addition, our
studies of clinical tumor specimens showed that the develop-
ment and progression of primary melanomas is also associated
with up-regulation of OPN and concomitant down-regulation
of CD9. These data strongly suggest that CD9 is a downstream
mediator of the OPN action in the promotion of the melanoma
cell migration/invasion and growth.
CD9 is known to interact with other tetraspanins and many
other transmembrane proteins, including various integrins
(a3b1, a4b1, a5b1, a6b1, and a6b4), growth factor receptors,
peptidases, and EWI proteins77e79; for a comprehensive list of
interacting proteins see PINA (Protein Interaction Network
Analysis platform query, http://cbg.garvan.unsw.edu.au/pina/
home.do, last accessed September 10, 2013). Thus, through
this tetraspanin web, CD9 may participate in a variety of
physiological and pathological processes. Abundant evidence
indicates that CD9 primarily acts as a tumor metastasis sup-
pressor,78,80 although opposite functions have also been re-
ported in some cases.78,81,82 A possible explanation of the
contradictory results may be that CD9 regulates only distinct
steps in the metastatic cascade78 or that its effects are context/
organ dependent.82 In any case, in experimental mouse models
of melanoma, the ectopic expression of CD9 in melanoma
cells83 and intratumoral injection of an adenoviral CD9
expression vector84 have been documented to inhibit the pul-
monary metastasis of melanoma cells. Of more physiological
relevance, in an orthotopic lung cancer model, the adenoviral
transduction of CD9 has been found to speciﬁcally inhibit
metastasis to the regional lymph nodes.85
There is also strong evidence for the involvement of CD9 in
various clinical cancers.78,80,81 The down-regulation or loss of
CD9 expression has been found to correlate with the inva-
siveness and/or metastasis of several cancers, including
breast,86 lung,87 prostate,88 and gastrointestinal89 cancers, and
melanoma.90 Further, high expression of CD9 has been
associated with good prognosis, and the down-regulation/loss
of CD9 with poor prognosis.89,91e94 Of particular interest, our
data suggest that the down-regulation of CD9 in the invasive
melanomas (which, consistent with a previous immunohisto-
chemical study,90 correlated with the increased thickness of
the primary tumors) is consequent to the increased expression
of OPN. It is of note that also in clinical tumors, the down-
regulation of CD9 appears to be primarily associated with
lymph nodemetastasis,91,95,96 similar to that observed with the
OPN-overexpressing tumor cells. Like OPN, CD9 has also
been found to regulate the adhesion, epithelial-mesenchymal
transition, migration/invasion, and proliferation/survival of
tumor cells.97e99 In addition, OPN and CD9 are known to
interact with and activate several proteins in common, such as
integrins, signaling proteins, and secreted proteases according
to PINA query (http://cbg.garvan.unsw.edu.au/pina/home.do,
last accessed September 10, 2013), that critically contribute to
the ability of tumor cells to invade and metastasize,38,78,81The American Journal of Pathology - ajp.amjpathol.orgalthough OPN and CD9 also display differences in their
interaction partners, eg, as to the binding of integrin avb3.
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Collectively, our data indicate that OPN regulates the acti-
vation state of av (b1, b3, and b5) integrins and down-regulates
the candidate metastasis suppressor CD9 in melanoma cells.
The overexpression of OPN and down-regulation of CD9 had
very similar consequences on the tumor cell behavior (growth
and invasion), ﬁtting with the idea that CD9 is an important
mediator of the OPN actions. However, both of these proteins
are multifunctional and apparently also have different mecha-
nisms of action, which is evident, for example, from the dif-
ferences in their binding partners and gene expression patterns
of the OPN- and CD9-overexpressing tumor cell lines.97,101
Therefore, it remains of interest to test whether a combinato-
rial therapeutic approach, ie, a concomitant inhibition of OPN
expression and activation of CD9 expression, particularly in the
early phase of metastasis, could result in increased efﬁcacy
(over that attainable by either intervention alone) in the pre-
vention of metastatic melanomas and other solid cancers.Acknowledgments
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